PA8472101A1 - Combinaciones terapeuticas para la fragilidad musculo esquelectica - Google Patents

Combinaciones terapeuticas para la fragilidad musculo esquelectica

Info

Publication number
PA8472101A1
PA8472101A1 PA19998472101A PA8472101A PA8472101A1 PA 8472101 A1 PA8472101 A1 PA 8472101A1 PA 19998472101 A PA19998472101 A PA 19998472101A PA 8472101 A PA8472101 A PA 8472101A PA 8472101 A1 PA8472101 A1 PA 8472101A1
Authority
PA
Panama
Prior art keywords
compositions
fragility
pharmaceutically acceptable
acceptable salt
skeletal muscle
Prior art date
Application number
PA19998472101A
Other languages
English (en)
Spanish (es)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8472101A1 publication Critical patent/PA8472101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PA19998472101A 1998-06-16 1999-05-07 Combinaciones terapeuticas para la fragilidad musculo esquelectica PA8472101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
PA8472101A1 true PA8472101A1 (es) 2000-09-29

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998472101A PA8472101A1 (es) 1998-06-16 1999-05-07 Combinaciones terapeuticas para la fragilidad musculo esquelectica

Country Status (29)

Country Link
EP (1) EP1085867A1 (de)
JP (1) JP2002518328A (de)
KR (1) KR20010052817A (de)
CN (1) CN1305378A (de)
AP (1) AP9901581A0 (de)
AR (1) AR018868A1 (de)
AU (1) AU3342099A (de)
BG (1) BG105128A (de)
BR (1) BR9911357A (de)
CA (1) CA2335112A1 (de)
CO (1) CO5070586A1 (de)
EA (1) EA200001189A1 (de)
GT (1) GT199900083A (de)
HR (1) HRP20000857A2 (de)
HU (1) HUP0102395A2 (de)
ID (1) ID26726A (de)
IL (1) IL139587A0 (de)
IS (1) IS5727A (de)
MA (1) MA26648A1 (de)
NO (1) NO20006381D0 (de)
OA (1) OA11569A (de)
PA (1) PA8472101A1 (de)
PE (1) PE20000633A1 (de)
PL (1) PL345064A1 (de)
SK (1) SK18902000A3 (de)
TN (1) TNSN99118A1 (de)
UY (1) UY25557A1 (de)
WO (1) WO1999065488A1 (de)
ZA (1) ZA993973B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (de) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen Agonisten/Antagonisten
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
ES2319785T3 (es) * 2001-11-29 2009-05-12 Gtx, Inc. Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
UY25557A1 (es) 2001-01-31
ID26726A (id) 2001-02-01
EP1085867A1 (de) 2001-03-28
IS5727A (is) 2000-11-24
WO1999065488A1 (en) 1999-12-23
PL345064A1 (en) 2001-11-19
TNSN99118A1 (fr) 2005-11-10
EA200001189A1 (ru) 2001-06-25
JP2002518328A (ja) 2002-06-25
PE20000633A1 (es) 2000-07-26
BG105128A (en) 2001-11-30
BR9911357A (pt) 2001-03-13
HUP0102395A2 (hu) 2001-11-28
KR20010052817A (ko) 2001-06-25
AP9901581A0 (en) 1999-06-30
IL139587A0 (en) 2002-02-10
HRP20000857A2 (en) 2001-10-31
NO20006381L (no) 2000-12-14
OA11569A (en) 2004-07-01
CN1305378A (zh) 2001-07-25
MA26648A1 (fr) 2004-12-20
CA2335112A1 (en) 1999-12-23
AU3342099A (en) 2000-01-05
AR018868A1 (es) 2001-12-12
NO20006381D0 (no) 2000-12-14
ZA993973B (en) 2000-12-15
SK18902000A3 (sk) 2001-12-03
CO5070586A1 (es) 2001-08-28
GT199900083A (es) 2000-12-05

Similar Documents

Publication Publication Date Title
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
PT1222195E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
GT199800083A (es) Agonistas de prostaglandinas.
PA8635901A1 (es) Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
GT199800106A (es) Azetidinas.
AR012193A1 (es) Nuevas combinaciones terapeuticas
PA8472101A1 (es) Combinaciones terapeuticas para la fragilidad musculo esquelectica
SE0101322D0 (sv) Novel compounds
PA8475901A1 (es) Terapia de combinacion para la fragilidad musculoesqueletica
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
HUP0204258A3 (en) Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
MX9204010A (es) Composicion farmaceutica que contiene 3(3-piridil)-1h,3-pirrol[1,2- c]tiazol-7-carboxamida y procedimiento para su preparacion.
TH48282A (th) การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน
ATE301455T1 (de) Pharmazeutische zubereitung enthaltend valaciclovir
UY26651A1 (es) Terapia combinada para la osteoporosis
ECSP972347A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ITMI20010971A0 (it) Formulazioni farmaceutiche e/o dietetiche contenenti colostro e uso del colostro per il trattamento dell'acne